Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells.

van Leeuwen IM, Rao B, Sachweh MC, Laín S.

Cell Cycle. 2012 May 1;11(9):1851-61. doi: 10.4161/cc.20254. Epub 2012 May 1.

2.

p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy.

Rao B, Lain S, Thompson AM.

Br J Cancer. 2013 Dec 10;109(12):2954-8. doi: 10.1038/bjc.2013.702. Epub 2013 Nov 14. Review.

3.

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.

Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP, Lain S.

Oncotarget. 2010 Nov;1(7):639-50.

4.

Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.

Miyachi M, Kakazu N, Yagyu S, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, Tsuchiya K, Iehara T, Hosoi H.

Clin Cancer Res. 2009 Jun 15;15(12):4077-84. doi: 10.1158/1078-0432.CCR-08-2955. Epub 2009 Jun 9.

5.

Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.

Choong ML, Yang H, Lee MA, Lane DP.

Cell Cycle. 2009 Sep 1;8(17):2810-8. Epub 2009 Sep 13.

PMID:
19657224
6.

Mechanism-specific signatures for small-molecule p53 activators.

van Leeuwen IM, Higgins M, Campbell J, Brown CJ, McCarthy AR, Pirrie L, Westwood NJ, Laín S.

Cell Cycle. 2011 May 15;10(10):1590-8. Epub 2011 May 15.

PMID:
21490429
7.

Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.

Rigatti MJ, Verma R, Belinsky GS, Rosenberg DW, Giardina C.

Mol Carcinog. 2012 May;51(5):363-78. doi: 10.1002/mc.20795. Epub 2011 May 6.

8.

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors.

Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT.

Cancer Res. 2005 Mar 1;65(5):1918-24.

9.

Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.

Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW.

Cancer Res. 2006 Mar 15;66(6):3169-76.

10.

Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.

Mochizuki H, Goto-Koshino Y, Sato M, Fujino Y, Ohno K, Tsujimoto H.

Vet Immunol Immunopathol. 2012 Jun 30;147(3-4):187-94. doi: 10.1016/j.vetimm.2012.04.017. Epub 2012 Apr 20.

PMID:
22578852
11.

MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.

Wang J, Zheng T, Chen X, Song X, Meng X, Bhatta N, Pan S, Jiang H, Liu L.

J Gastroenterol Hepatol. 2011 Feb;26(2):371-7. doi: 10.1111/j.1440-1746.2010.06440.x.

PMID:
21261729
12.

p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma.

Roh JL, Kang SK, Minn I, Califano JA, Sidransky D, Koch WM.

Oral Oncol. 2011 Jan;47(1):8-15. doi: 10.1016/j.oraloncology.2010.10.011. Epub 2010 Dec 15.

13.

Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.

Palani CD, Beck JF, Sonnemann J.

Invest New Drugs. 2012 Feb;30(1):25-36. doi: 10.1007/s10637-010-9510-7. Epub 2010 Aug 3.

PMID:
20680659
14.

Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture.

Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV.

Oncotarget. 2011 Mar;2(3):222-33.

15.

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J Jr, Cuvelier CA, Marine JC, De Paepe A, Bracke M, Speleman F, Vandesompele J.

J Natl Cancer Inst. 2009 Nov 18;101(22):1562-74. doi: 10.1093/jnci/djp355. Epub 2009 Nov 10.

PMID:
19903807
16.

DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.

Zhang CC, Yang JM, Bash-Babula J, White E, Murphy M, Levine AJ, Hait WN.

Cancer Res. 1999 Aug 1;59(15):3663-70.

17.

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.

Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK.

Oncogene. 2007 May 24;26(24):3473-81. Epub 2006 Dec 4.

PMID:
17146434
18.

MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.

Canner JA, Sobo M, Ball S, Hutzen B, DeAngelis S, Willis W, Studebaker AW, Ding K, Wang S, Yang D, Lin J.

Br J Cancer. 2009 Sep 1;101(5):774-81. doi: 10.1038/sj.bjc.6605199.

19.

Differential regulation of p21 (waf1) protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications.

Chang LJ, Eastman A.

Cancer Biol Ther. 2012 Sep;13(11):1047-57. doi: 10.4161/cbt.21047. Epub 2012 Jul 24.

20.

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).

Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, Ford RJ Jr, Vega F, Medeiros LJ.

Leukemia. 2011 May;25(5):856-67. doi: 10.1038/leu.2011.28. Epub 2011 Mar 11.

Supplemental Content

Support Center